Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
AUTOR(ES)
Patterson, T F
RESUMO
The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with SCH at 10 or 15 mg/kg of body weight per day was begun 24 h after lethal challenge and compared with therapy with amphotericin B at 1.5 mg/kg/day. Compared with untreated controls, SCH reduced mortality and also reduced the tissue burden of A. fumigatus 100- to 1,000-fold in liver, kidney, and lung tissues. SCH at 15 mg/kg/day and amphotericin B eliminated A. fumigatus in liver, kidney, and lung tissues. In addition, both dosages of SCH significantly eliminated the organism from brain tissues, compared with controls. Both SCH and amphotericin B decreased or eliminated circulating aspergillus antigen. These results show that new azoles can be as effective as amphotericin B in eradicating the organism from tissues and offer promise in improving the treatment of invasive aspergillosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=245312Documentos Relacionados
- Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
- Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
- Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.
- Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.
- Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis
